Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2004;109:1590-1593
Published online before print March 29, 2004, doi: 10.1161/01.CIR.0000125521.40985.28
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
109/13/1590    most recent
01.CIR.0000125521.40985.28v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Williams, M. L.
Right arrow Articles by Koch, W. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Williams, M. L.
Right arrow Articles by Koch, W. J.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Genes and Gene Therapy
*Heart Failure
Related Collections
Right arrow Contractile function
Right arrow Congestive
Right arrow Other Treatment
Right arrow Chronic ischemic heart disease

(Circulation. 2004;109:1590-1593.)
© 2004 American Heart Association, Inc.


Brief Rapid Communication

Targeted ß-Adrenergic Receptor Kinase (ßARK1) Inhibition by Gene Transfer in Failing Human Hearts

Matthew L. Williams, MD*; Jonathan A. Hata, MD*; Jacob Schroder, MD; Edward Rampersaud, MD; Jason Petrofski, MD; Andre Jakoi, BS; Carmelo A. Milano, MD; Walter J. Koch, PhD

From the Department of Surgery, Duke University Medical Center (M.L.W., J.A.H., J.S., E.R., J.P., A.J., C.A.M., W.J.K.), Durham, NC; Department of Surgery, Massachusetts General Hospital (M.L.W.), Boston, Mass; and Center for Translational Medicine (W.J.K.), Thomas Jefferson University, Philadelphia, Pa.

Correspondence to Walter J. Koch, PhD, FAHA, Director, Center for Translational Medicine, Jefferson Medical College, 1025 Walnut St, Room 410, Philadelphia, PA 19107. E-mail walter.koch{at}jefferson.edu

Received December 16, 2003; revision received February 12, 2004; accepted February 18, 2004.

Background— Failing human myocardium is characterized by an attenuated contractile response to ß-adrenergic receptor (ßAR) stimulation due to changes in this signaling cascade, including increased expression and activity of the ß-adrenergic receptor kinase (ßARK1). This leads to desensitization and downregulation of ßARs. Previously, expression of a peptide inhibitor of ßARK1 (ßARKct) has proven beneficial in several animal models of heart failure (HF).

Methods and Results— To test the hypothesis that inhibition of ßARK1 could improve ß-adrenergic signaling and contractile function in failing human myocytes, the ßARKct was expressed via adenovirus-mediated (AdßARKct) gene transfer in ventricular myocytes isolated from hearts explanted from 10 patients with end-stage HF undergoing cardiac transplantation. AdßARKct also contained the marker gene, green fluorescent protein, and successful gene transfer was confirmed via fluorescence and immunoblotting. Compared with uninfected failing myocytes (control), the velocities of both contraction and relaxation in the AdßARKct-treated cells were increased in response to the ß-agonist isoproterenol (contraction: 57.5±6.6% versus 37.0±4.2% shortening per second, P<0.05; relaxation: 43.8±5.5% versus 27.5±3.9% lengthening per second, P<0.05). Fractional shortening was similarly enhanced (12.2±1.2% versus 8.0±0.9%, P<0.05). Finally, adenylyl cyclase activity in response to isoproterenol was also increased in AdßARKct-treated myocytes.

Conclusions— These results demonstrate that as in animal models of HF, expression of the ßARKct can improve contractile function and ß-adrenergic responsiveness in failing human myocytes. Thus, ßARK1 inhibition may represent a therapeutic strategy for human HF.


Key Words: myocytes • heart failure • gene therapy




This article has been cited by other articles:


Home page
Circ. Res.Home page
L. E. Vinge, P. W. Raake, and W. J. Koch
Gene Therapy in Heart Failure
Circ. Res., June 20, 2008; 102(12): 1458 - 1470.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
C. Perrino, J. N. Schroder, B. Lima, N. Villamizar, J. J. Nienaber, C. A. Milano, and S. V. Naga Prasad
Dynamic Regulation of Phosphoinositide 3-Kinase-{gamma} Activity and -Adrenergic Receptor Trafficking in End-Stage Human Heart Failure
Circulation, November 27, 2007; 116(22): 2571 - 2579.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
T. Tang and H. K. Hammond
Cell-Based GATA4 Cardiac Gene Transfer Using Cell-Penetrating Peptide
Circ. Res., June 8, 2007; 100(11): 1540 - 1542.
[Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
M. A. Nordlie, L. E. Wold, B. Z. Simkhovich, C. Sesti, and R. A. Kloner
Molecular Aspects of Ischemic Heart Disease: Ischemia/Reperfusion-Induced Genetic Changes and Potential Applications of Gene and RNA Interference Therapy
Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2006; 11(1): 17 - 30.
[Abstract] [PDF]


Home page
Exp PhysiolHome page
C. Nakajima-Takenaka, S. Sakata, S. Kato, Y. Ohga, K.-y. Murata, S. Taniguchi, and M. Takaki
Detrimental effects after dobutamine infusion on rat left ventricular function: mechanical work and energetics
Exp Physiol, July 1, 2005; 90(4): 635 - 644.
[Abstract] [Full Text] [PDF]